Key points
- Successful private placement of ~$2M to existing shareholders
- Funds to support growth initiatives, including NeuroNode Only and NeuroStrip
- Strengthening balance sheet to accelerate commercialization and drive long-term value
Full summary
Control Bionics Limited (ASX: CBL) has successfully raised approximately A$2.0 million via a private placement to two existing shareholders, Nightingale Partners Pty Ltd and Phoenix Development Fund Limited. The placement was conducted at an issue price of A$0.045 per share, representing a strong endorsement of the company's strategic direction and growth potential. The funds raised will be used to support Control Bionics' continued focus on revenue growth in its core operations and the expansion into new high-potential markets, including NeuroNode Only and NeuroStrip. These innovative product offerings present significant opportunities for the company to diversify its revenue base and establish a stronger presence in assistive technology, sports performance, and rehabilitation markets. The additional capital will enable the company to continue scaling its NeuroNode and NeuroStrip businesses across key global markets, support ongoing product development and commercialization efforts, and strengthen operational execution to drive revenue growth and profitability. The company remains committed to executing a disciplined growth strategy, ensuring that Control Bionics maximizes the commercial potential of its proprietary technology and delivers sustainable value to shareholders.
Outlook
With a growing pipeline of commercial opportunities and a strengthened balance sheet, Control Bionics is well-positioned to accelerate its revenue trajectory and build momentum in its core and emerging markets. The company looks forward to updating shareholders on further developments as it progresses towards achieving key milestones in 2025 and beyond.